sim0505
·Code: SIM0505, SCR-9359
sim0505: sourced relationships with 1 company · 1 clinical trial tracked.
sim0505 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect sim0505 to NXTC; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could sim0505 → NXTC affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| NextCure, Inc. (NXTC) | Phase 1 |
Clinical Trial Registry Records (1)
A Phase I First-in-human, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants With Advanced Solid Tumors
Primary endpoint: dose escalation: Dose-limiting toxicity (DLT)
InterventionalRandomizedopen738 targetStarted 2025-02Completion 2028-0817 sites · China, United StatesNextCure, Inc.
Frequently asked questions
Which companies have sourced relationships with sim0505?
sim0505 has dated SEC/FDA relationship records for NextCure, Inc..
How many clinical trials involve sim0505?
BioSniper tracks 1 clinical trial involving sim0505.